TY - JOUR T1 - Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. <em>vs</em> 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial JF - medRxiv DO - 10.1101/2021.11.17.21266488 SP - 2021.11.17.21266488 AU - Nuccia Morici AU - GianMarco Podda AU - Simone Birocchi AU - Luca Bonacchini AU - Marco Merli AU - Michele Trezzi AU - Gianluca Massaini AU - Marco Agostinis AU - Giulia Carioti AU - Francesco Saverio Serino AU - Gianluca Gazzaniga AU - Daniela Barberis AU - Laura Antolini AU - Maria Grazia Valsecchi AU - Marco Cattaneo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/21/2021.11.17.21266488.abstract N2 - It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. vs 40 mg o.d. enoxaparin in COVID-19 patients, between April 30, 2020 and April 25, 2021. Primary efficacy outcome was in-hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding. The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6·5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6·5, 95% CI, 1·5-11·6). Absence of concomitant DVT and imaging characteristics suggest that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically non-significant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm. In conclusion, no DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.REGISTRATION ClinicalTrials.gov Identifier: NCT04366960Ethics Commettee approvation number 75/2020Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04366960Funding StatementItalfarmaco. The funding source had no roles in study design, data collection, data access, data analysis, data interpretation, decision to writing of the report and submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ASST Grande Ospedale Metropolitano Niguarda gave ethical approval for this work. Ethics Commettee approvation number: 75/2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -